Healthcare
Shield Therapeutics plc(SHIEF)
Live Price
Offline$0.08
+0.00% today
1Y Change
+131.21%
Window
Jun 23, 2025 โ Jun 15, 2026
- Market Cap
- $110.00M
- Revenue Growth
- +57.9%
- EPS Growth
- +31.7%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 23, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Shield Therapeutics plc (SHIEF) is a Healthcare stock with a market cap of $110.00M and listed on OTC. The stock last traded around $0.08 and up 131.2% across the available one-year price window (Jun 23, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +57.9%, EPS growth of +31.7%, a dividend yield of 0.0%. What stands out right now is revenue +57.9%, EPS +31.7%, free cash flow +3.8% with operating margin -19.5% and ROIC -58.3%. Valuation is more restrained than many high-expectation growth names at price/sales 2.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SHIEF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+57.9% vs +7.6% peer median
Operating Margin
Below sector median
-19.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 23, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +57.9% and EPS at +31.7%, with operating margin around -19.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +7.5% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 23, 2026 | โ | +0.0% | +0.0% | -43.8% |
2025 Apr 24, 2025 | +61.4% | +0.0% | +11.3% | +11.3% |
2024 Sep 4, 2024 | โ | +0.0% | +11.3% | +11.3% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SHIEF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SHIEF Max Drawdown
-52.35%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SHIEF and SPY.
Company Overview
Shield Therapeutics plc
Other OTC
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company was founded in 2008 and is based in Gateshead, the United Kingdom.
- Leadership
- Anders Lundstrom
- IPO Date
- Dec 6, 2019
- Employees
- 63
- Street Address
- Northern Design Centre
- Mailing
- Gateshead, NE8 3DF
- Region
- Gateshead, GB
- Reporting Currency
- USD
- Investor Line
- 44 1915 118 500
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 2.6
- Price/Book
- โ
Growth
- Revenue
- +57.9%
- EPS
- +31.7%
- Free Cash Flow
- +3.8%
Profitability
- Gross Margin
- 43.9%
- Operating Margin
- -19.5%
- Net Margin
- -34.5%
- ROE
- 103.6%
- ROIC
- -58.3%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.90
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.